Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Altus Pharmaceuticals, Inc.
Phase I study of growth hormone completed
July 6th, 2005
Altus Pharmaceuticals, Inc., has successfully completed clinical testing in the phase I study for ALTU-238, a long-acting crystalline formulation of recombinant human growth hormone (somatropin). The study was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of ALTU-238 in normal healthy volunteers. The company also announced it plans to initiate a multicenter phase II clinical trial to study the safety and biological activity of repeated doses of ALTU-238 in adults with growth hormone deficiency. Sheldon Berkle, president and CEO of Altus Pharmaceuticals said, "We believe that ALTU-238 will...
Source: Biotech Week (2005-07-06)
|
